Clinical Report: Gilead and Merck's Recent Clinical Trial Outcomes

Overview

Gilead and Merck reported successful outcomes for an experimental HIV treatment that suppresses the virus with weekly dosing. However, a Phase 3 trial for a lung cancer combination therapy was halted due to lack of efficacy.

Background

The development of longer-acting HIV treatments is crucial for improving patient adherence and convenience, potentially transforming HIV management. Conversely, setbacks in oncology trials highlight the challenges faced in developing effective cancer therapies, particularly in competitive markets.

Data Highlights

No numerical data available in the source material.

Key Findings

• The experimental HIV pill successfully suppressed the virus in two large trials.
• The HIV treatment combines Merck’s islatravir and Gilead’s lenacapavir.
• The Phase 3 study EVOKE-03 was terminated early due to lack of significant improvement in progression-free survival.
• Trodelvy, an antibody used in the lung cancer trial, is already approved for certain breast cancers.
• Merck is developing a competing TROP-2-targeted antibody that has shown promising results in lung cancer.

Clinical Implications

The successful trial outcomes for the HIV treatment may lead to more convenient options for patients, enhancing adherence to therapy. The failure of the lung cancer trial underscores the need for continued innovation and evaluation in cancer treatment strategies.

Conclusion

The contrasting outcomes of Gilead and Merck's recent trials illustrate the complexities of drug development in both HIV and oncology. Continued research and collaboration are essential for advancing treatment options.

Related Resources & Content

1. CDC, MMWR, 2025 -- Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis
2. Merck, 2025 -- U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir
3. Gilead, 2024 -- Magrolimab Trials Summary
4. The ASCO Post — Expert Point of View: A. Craig Lockhart, MD
5. The ASCO Post — Expert Point of View: Toni K. Choueiri, MD
6. The ASCO Post — Global Trials: Do Benefits Outweigh Pitfalls?
7. The ASCO Post — Expert Point of View: Justin F. Gainor, MD
8. Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis — United States, 2025 | MMWR
9. GUIDELINES FOR THE USE OF
10. Lenacapavir as pre‐exposure prophylaxis for HIV prevention - PMC
11. U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection - Merck.com
12. ENHANCE-3 - Health Research Authority
13. US FDA puts Gilead’s magrolimab trials on clinical hold
14. Magrolimab is an investigational agent that has been studied in three separate Phase 3
15. Oncology (Cancer)/Hematologic Malignancies Approval Notifications | FDA
16. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer | New England Journal of Medicine
17. FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma | FDA
18. KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment - Merck.com
19. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
20. Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial - Merck.com
21. Merck’s gefapixant gets second CRL for chronic cough | BioWorld
22. Lyfnua | European Medicines Agency (EMA)